In the past week, STTK stock has gone down by -3.65%, with a monthly decline of 0.00% and a quarterly surge of 30.69%. The volatility ratio for the week is 26.54%, and the volatility levels for the last 30 days are 13.27% for Shattuck Labs Inc The simple moving average for the past 20 days is 0.82% for STTK’s stock, with a -54.71% simple moving average for the past 200 days.
Is It Worth Investing in Shattuck Labs Inc (NASDAQ: STTK) Right Now?
The 36-month beta value for STTK is also noteworthy at 1.68. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for STTK is 40.71M, and at present, short sellers hold a 4.71% of that float. The average trading volume of STTK on March 03, 2025 was 228.20K shares.
STTK) stock’s latest price update
Shattuck Labs Inc (NASDAQ: STTK) has experienced a rise in its stock price by 10.92 compared to its previous closing price of 1.19. However, the company has seen a fall of -3.65% in its stock price over the last five trading days. globenewswire.com reported 2025-02-20 that – SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study – – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 – AUSTIN, TX & DURHAM, NC, Feb. 20, 2025 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced positive preclinical data from an IND-enabling GLP toxicology study of SL-325 in non-human primates (NHP). These data were featured in a digital oral presentation on February 20, 2025, during the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 in Berlin, Germany.
Analysts’ Opinion of STTK
Citigroup, on the other hand, stated in their research note that they expect to see STTK reach a price target of $2, previously predicting the price at $8. The rating they have provided for STTK stocks is “Neutral” according to the report published on October 02nd, 2024.
STTK Trading at 7.62% from the 50-Day Moving Average
After a stumble in the market that brought STTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.78% of loss for the given period.
Volatility was left at 13.27%, however, over the last 30 days, the volatility rate increased by 26.54%, as shares surge +5.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.79% upper at present.
During the last 5 trading sessions, STTK fell by -3.65%, which changed the moving average for the period of 200-days by -87.33% in comparison to the 20-day moving average, which settled at $1.3092. In addition, Shattuck Labs Inc saw 9.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at STTK starting from Redmile Group, LLC, who purchase 133,371 shares at the price of $1.25 back on Dec 04 ’24. After this action, Redmile Group, LLC now owns 5,539,724 shares of Shattuck Labs Inc, valued at $166,714 using the latest closing price.
Redmile Group, LLC, the Director of Shattuck Labs Inc, sale 133,371 shares at $1.25 during a trade that took place back on Dec 04 ’24, which means that Redmile Group, LLC is holding 5,406,353 shares at $166,714 based on the most recent closing price.
Stock Fundamentals for STTK
Current profitability levels for the company are sitting at:
- -12.41 for the present operating margin
- -2.29 for the gross margin
The net margin for Shattuck Labs Inc stands at -11.56. The total capital return value is set at -0.8. Equity return is now at value -71.09, with -61.46 for asset returns.
Based on Shattuck Labs Inc (STTK), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -17.31. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -85.25.
Currently, EBITDA for the company is -87.61 million with net debt to EBITDA at 0.53. When we switch over and look at the enterprise to sales, we see a ratio of 3.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.96.
Conclusion
In summary, Shattuck Labs Inc (STTK) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
